Skip to main content

#161202

MCF10A-ERRB2m-13 cell line

Cat. #161202

MCF10A-ERRB2m-13 cell line

Cat. #: 161202

Sub-type: Continuous

Availability: 8-10 weeks

Organism: Human

Tissue: Mammarygland epithelium

Model: Mutant

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Medical-Industrial Translational Research Center

Institute: Fukushima Medical University

Primary Citation: Irie et al. Mol Cancer Ther. 2019 Apr, 18(4):733-742. PMID: 30787176

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: MCF10A-ERRB2m-13 cell line
  • Alternate name: 06M15027
  • Cancers detailed: Non-tumorigenic
  • Research fields: Cancer;Cell biology
  • Tool sub type: Continuous
  • Parental cell: MCF10A, a non-tumorigenic cell line from human mammarygland epithelium
  • Clone: ERBB2_type-15
  • Organism: Human
  • Tissue: Mammarygland epithelium
  • Morphology: Epithelial
  • Growth properties: Adherent
  • Model: Mutant
  • Model description: Type-15; Type mutation: P780_Y781insGSP; CDS mutation: c.2339_2340insGGGCTCCCC; AA mutation: p.P780_Y781insGSP; COSMIC Mutation ID: COSM12555
  • Description: Non-tumorigenic immortalized breast epithelial cell stably overexpressing mutant cancer-related gene, ERBB2 (erb-B2 Receptor Tyrosine Kinase 2). ERBB2 is a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors.
  • Application: Functional analysis of mutated genes, Drug screening
  • Biosafety level: 1

Target Details

  • Target: Erb-b2 receptor tyrosine kinase 2 [ERBB2]
  • Target background: Gene ID: 2064; References: DNA (mRNA): NM_004448.3; Protein: NP_004439.2

Applications

  • Application: Functional analysis of mutated genes, Drug screening

Handling

  • Format: Frozen
  • Growth medium: DMEM/Ham's F-12 supplemented with 5% heat-inactivated horse serum, 10 Â?g/ml insulin (human, recombinant), 5 Â?M forskolin, 0.5 Â?g/ml hydrocortisone, 20 ng/ml EGF (human, recombinant), 100 U/ml penicillin, and 100 Â?g/ml streptomycin
  • Temperature: 37° C
  • Atmosphere: Humidified incubator with 5% CO2
  • Shipping conditions: Dry ice
  • Storage medium: CELLBANKER 2 (Zenogen pharma)
  • Storage conditions: Liquid Nitrogen
  • Initial handling information: Thaw the vial at 37 °C in a water bath?then seed cells into a T75 flask. Culture in a humidified Incubator at 37 ? with 5% CO2 in air. Culture medium should be changed every 2 to 3 days.
  • Cultured in antibiotics: 100 U/ml Penicillin, and 100 Â?g/ml Streptomycin
  • Mycoplasma free: Yes
  • Characterisation tests: Comprehensive gene expression analysis; Identification of cell proliferation and cellular form; Drug sensitivity tests

References

  • Irie et al. Mol Cancer Ther. 2019 Apr, 18(4):733-742. PMID: 30787176

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.